Hashimoto’s Disease Plasma

Hashimoto’s Disease Plasma for Autoimmune Thyroid Research

Hashimoto’s Disease Plasma is collected from IRB-consented donors clinically diagnosed with Hashimoto’s thyroiditis and processed within one day of collection to preserve labile analytes such as cytokines, proteins, and metabolites. Anticoagulant type and aliquot volume are configured per project and reported per lot. This plasma supports research into autoimmune thyroid destruction, the systemic consequences of thyroid hormone deficiency, and biomarker discovery across the natural history of the disease. Bulk plasma is available.

Why Plasma for Hashimoto’s Thyroiditis Research

Hashimoto’s disease is a genuine autoimmune disorder: the immune system mounts a sustained response against thyroid tissue, producing lymphocytic infiltration of the gland and progressive loss of functioning thyrocytes. It is the most common cause of hypothyroidism in iodine-sufficient populations. Circulating specimens are the practical window onto this process, because the thyroid itself is rarely biopsied in research settings.

  • Autoantibodies against thyroid peroxidase and thyroglobulin are the defining serological markers of Hashimoto’s disease, and their presence and titre are how donors are stratified into biologically meaningful groups.
  • Thyroid autoimmunity progresses through recognisable stages — autoantibody-positive euthyroidism, subclinical hypothyroidism with a raised TSH and preserved free T4, and overt hypothyroidism — so plasma from donors at different stages supports research into what drives progression.
  • Plasma is collected without a clotting step, which preserves coagulation-sensitive analytes and makes it the preferred matrix for many cytokine, proteomic, and metabolomic platforms; classical thyroid autoantibody and thyroid function serology is conventionally run on serum, and both matrices can be supplied from the same donor.
  • Thyroid hormone deficiency has broad metabolic consequences, including effects on lipid handling, which makes plasma from untreated and treated donors useful for metabolic and cardiovascular biomarker work.
  • Hashimoto’s disease clusters with other autoimmune conditions such as celiac disease, type 1 diabetes, vitiligo, and pernicious anaemia, so these cohorts support research into shared autoimmune mechanisms and polyautoimmunity.
  • Levothyroxine replacement normalises hormone levels without removing the underlying autoimmunity, allowing the immunological and the endocrine components of the disease to be separated in a treated cohort.

Donor Stratification Available

  • Thyroid autoantibody status and titre: anti-thyroid peroxidase and anti-thyroglobulin, where documented
  • Biochemical stage: euthyroid with positive autoantibodies, subclinical hypothyroidism, or overt hypothyroidism
  • Treatment status: levothyroxine-treated and biochemically controlled, treated and uncontrolled, or untreated
  • Goitrous or atrophic presentation where recorded
  • Concurrent autoimmune conditions and family history of autoimmune disease
  • Disease duration, age band, and sex assigned at birth
  • Matched healthy controls available, including autoantibody-negative donors

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed Hashimoto’s disease donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Anticoagulant type specified at order where inventory permits
  • Custom aliquot volumes available upon request
  • Volumes and lot-specific processing details reported per lot

De-identified Donor Data

  • Verified Hashimoto’s disease diagnosis
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Thyroid function and autoantibody results where available
  • Additional Hashimoto’s disease-specific metadata available on request

Applications

  • Thyroid autoantibody assay development, calibration, and specificity testing
  • Biomarker discovery for progression from subclinical to overt hypothyroidism
  • Cytokine and inflammatory mediator profiling in autoimmune thyroid disease
  • Proteomic and metabolomic characterisation of the hypothyroid state
  • Lipid and cardiometabolic biomarker research in treated and untreated donors
  • Polyautoimmunity research alongside other autoimmune cohorts
  • Treatment-response and levothyroxine adequacy studies
  • Control and comparator material for non-autoimmune hypothyroidism studies

Other Hashimoto’s Disease Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Hashimoto’s disease plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other disease states and collection formats, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information